Clinical Trials Sponsored by Argo Sante

Total 3202 results

Argo Sante
GenSight Biologics

Completed

Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection

Leber's Hereditary Optic Neuropathy (LHON)

France
Argo Sante
Filière de santé maladies rares MCGRE; Fédération des malades drépanocytaires... and other collaborators

Completed

Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France (DREPAtient)

Sickle-cell Disease (SCD)

France
CARGO Therapeutics

Recruiting

A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma

Cancer | Relapsed/Refractory Large B-cell Lymphoma (LBCL)

United States
Laboratoires URGO

Completed

Assessment of Efficacy & Tolerance of Urgo 310 3166 Dressing in Local Venous or Mixed Leg Ulcers (CASSIOPEE)

Ulcers, Leg

France
Laboratoires URGO

Unknown

Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers (DISCOVERY)

Diabetic Foot Ulcer

Czechia, France, Italy, Poland, Spain, United Kingdom
Laboratoires URGO

Unknown

HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer (HEAL)

Wound
Argos Therapeutics

Terminated

A Rollover Protocol for Subjects Previously Treated With AGS-003

Renal Cell Carcinoma

United States
Laboratoires URGO

Unknown

Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers

Diabetic Foot Ulcer(s)

France
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Renal Cell Carcinoma

United States, Canada
Argos Therapeutics

Completed

RNA-Loaded Dendritic Cell Cancer Vaccine

Renal Cell Carcinoma

United States, Canada
Laboratoires URGO

Recruiting

Clinical Evaluation in Real Life of TLC-NOSF Dressings in the Local Treatment of Chronic Wounds (DFU and VLU) (STARTLIFE)

Diabetic Foot Ulcer | Venous Leg Ulcer | Real Life Study | TLC-NOSF Dressings | QoL Questionnaire

France
Laboratoires URGO

Recruiting

Efficacy and Tolerance of URGO AWC_008 and URGO AWC_022 Dressings (EXPANSION)

Wound Infection | Diabetic Foot Ulcer | Venous Leg Ulcer | Pressure Ulcer | Acute Wounds

France
Laboratoires URGO

Completed

Efficacy and Safety of URGOBD001 Compression System (FUTURE)

Venous Leg Ulcer

France
Argos Therapeutics

Completed

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Kidney Cancer | Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States
Laboratoires URGO

Unknown

Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers

Leg Ulcers

France
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Androgen-independent Prostate Cancer

United Kingdom
Laboratoires URGO

Completed

Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.

Varicose Ulcer

France
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Renal Cell Carcinoma

Canada, United States
Argos Therapeutics

Completed

A Single-Patient Study Using AGS 006

Pancreatic Cancer

United States
Argos Therapeutics

Completed

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

HIV Infections

Canada, United States
Argos Therapeutics

Completed

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus (SLE)

United States
Laboratoires URGO

Unknown

Efficacy and Safety of a New Compression System URGO BD001 in the Treatment of VLU (FREEDOM) (FREEDOM)

Venous Leg Ulcer
Laboratoires URGO

Unknown

Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects (FUSION)

Healthy Subjects

France
Laboratoires URGO

Unknown

Management of Infection Risk in Non-comparative Trial (MINT) (MINT)

Venous Leg Ulcer
Argos Therapeutics

Terminated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Israel, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
Argos Therapeutics

Completed

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

HIV Infection

United States, Canada
Arno Therapeutics

Unknown

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy

France
Arno Therapeutics

Unknown

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

Glioblastoma Multiforme | Gliosarcoma | GBM

United States, Canada
Arno Therapeutics

Unknown

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Arno Therapeutics

Completed

Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma

Lymphoma | Solid Tumors

United States, United Kingdom
Laboratoires URGO

Unknown

Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children

Attention Deficit Hyperactivity Disorder

France
Arga Medtech SA

Recruiting

Coherent Sine Burst (CSE) Electroporation System Pilot Study in Patients With Atrial Fibrillation (BURST-AF)

Atrial Fibrillation

Georgia
Arog Pharmaceuticals, Inc.

Completed

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States
Arog Pharmaceuticals, Inc.

Completed

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Recurrent/Refractory Glioblastoma

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

United States
Arog Pharmaceuticals, Inc.

Available

Individual Patient Compassionate Use of Crenolanib

FLT3-ITD Mutation | FLT3/TKD Mutation | PDGFR-Alpha D842V | PDGFRA Gene Amplification

Italy
Arog Pharmaceuticals, Inc.

Completed

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
Arog Pharmaceuticals, Inc.

Recruiting

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Newly Diagnosed FLT3 Mutated AML

United States
Arog Pharmaceuticals, Inc.

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada
Arog Pharmaceuticals, Inc.

Withdrawn

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Relapsed/Refractory FLT3-mutated AML
Arog Pharmaceuticals, Inc.

Terminated

Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Glioma

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

D842-related Mutant GIST

United States
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

United States
Arog Pharmaceuticals, Inc.

Completed

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Newly Diagnosed AML With FLT3 Activating Mutations

United States
Arog Pharmaceuticals, Inc.

Completed

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States
Arog Pharmaceuticals, Inc.

Completed

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

United States
Arog Pharmaceuticals, Inc.

Withdrawn

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Carcinoma, Non-Small-Cell Lung
Aro Biotherapeutics

Recruiting

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Healthy

Canada
ARO Medical

Unknown

Safety Study of ARO Spinal System as an Adjunct to Lumbar Decompression

Lumbar Disc Prolapse With Radiculopathy

Denmark

3

Subscribe